No Data
No Data
TFF Pharmaceuticals Enters Pact for Dry Powder MRNA-based Covid Treatment
Express News | TFF Pharmaceuticals Announced Its New Partnership With Emory University And The Biomedical Advanced Research And Development Authority To Develop A Dry Powder Inhaled Mrna-based Treatment For Influenza And Covid
TFF Pharmaceuticals Announces Positive Preclinical Data From Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
TFF Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
TFF Pharmaceuticals GAAP EPS of -$1.22 Misses by $0.41, Revenue of $0.65M Beats by $0.5M
No Data
No Data